MDXH vs RPID
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.
RPID exhibits severe fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and a complete lack of profitability. While the company shows strong top-line revenue growth (37.3% YoY) and maintains a healthy current ratio (3.31), these are overshadowed by an abysmal gross margin of 3.12% and negative profit margins of -140.30%. The stark divergence between the 'Strong Buy' analyst consensus and the aggressive insider selling by the CEO, CFO, and COO suggests a significant disconnect between market expectations and internal sentiment.
Compare Another Pair
Related Comparisons
MDXH vs RPID: Head-to-Head Comparison
This page compares MDxHealth SA (MDXH) and Rapid Micro Biosystems, Inc. (RPID) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.